Literature DB >> 32192790

Cardiovascular consequences of parathyroid disorders in adults.

Jens Bollerslev1, Evelina Sjöstedt2, Lars Rejnmark3.   

Abstract

PTH is a metabolic active hormone primarily regulating calcium and phosphate homeostasis in a very tight and short term-manner. Parathyroid disorders in adult patients reflect a variety of different conditions related either to the parathyroid glands itself or to the effects of the secreted hormone. The clinical spectrum varies from the common disease primary hyperparathyroidism (PHPT) to the orphan conditions pseudohypoparathyroidism (Ps-HypoPT) and chronic hypoparathyroidism (HypoPT). The purpose of this review is to describe the consequences of disturbances in levels or action of PTH for cardiac function and cardiovascular risk in adult patients with these disorders. Most patients with PHPT achieve the diagnose by chance and have minor or no specific symptoms. Still, these patients with mild PHPT do possess cardiovascular (CV) morbidity, however so far not proven ameliorated by surgery in controlled trials. In severe cases, the CV risk is increased and with a potential reversibility by treatment. Patients with Ps-HypoPT have resistance to PTH action, but not necessarily total resistance in all tissues. So far, no clear CV morbidity or risk has been demonstrated, but there are several aspects of interest for further studies. Most patients with HypoPT do get their hormonal deficiency syndrome following neck surgery. These patients do experience multiple symptoms and do have an increased CV-risk before the primary surgery. Based on existing data, their CV mortality do not deviate from the expected when adjusting for the preexisting increased risk. Patients with nonsurgical (NS-) HypoPT do demonstrate increased CV-risk also associated with exposure time. Endocrine disorders with alterations in PTH function have major impact on the cardiovascular system of importance for morbidity and mortality, wherefore management of these specific diseases should be optimized currently, as new data become available, however also avoiding over-treating asymptomatic patients.
Copyright © 2020. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Calcium; Cardiovascular; Heart; Hyperparathyroidism; Hypoparathyroidism; PTH; Pseudohypoparathyroidism

Mesh:

Year:  2020        PMID: 32192790     DOI: 10.1016/j.ando.2020.02.003

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  3 in total

1.  Parathyroid Hormone Promotes Human Umbilical Vein Endothelial Cell Migration and Proliferation Through Orai1-Mediated Calcium Signaling.

Authors:  Shuhao Wang; Lijie Xu; Yv Wu; Hailong Shen; Zhangying Lin; Yang Fang; Lesha Zhang; Bing Shen; Yehai Liu; Kaile Wu
Journal:  Front Cardiovasc Med       Date:  2022-03-16

2.  Hypertrophic cardiomyopathy in a patient with secondary hypoparathyroidism: A case report.

Authors:  Juan Felipe Betancur; Christian Adams-Sánchez; Lina Restrepo-Giraldo; Joel Arévalo-Novoa; Beatriz Ramírez; Juan Felipe Llano; Gustavo Adolfo López
Journal:  Radiol Case Rep       Date:  2022-09-28

Review 3.  Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach.

Authors:  Guido Zavatta; Bart L Clarke
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.